VEGFA and non-small cell lung carcinoma: By using top 10% targets of vitexicarpin, we also found significantly enriched KEGG pathways vitexicarpin may affect cancer-related pathways (e.g., Non-small cell lung cancer, Prostate cancer, Glioma, Pathways in cancer, etc.), T cell receptor signaling pathway, and VEGF signaling pathway.